Myasthenia gravis trials in Germany

In Germany 22 Also abroad 123

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Bochum, Essen, Goettingen, Jena, Leipzig, Rüdersdorf, Wuerzburg
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Bochum, Essen, Goettingen, Jena, Leipzig, Rüdersdorf, Wuerzburg
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Berlin, Goettingen, Ulm
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
No phaseTaking people
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Where
Berlin, Bochum, München
Age
18 years and over
People
100 worldwide
Run by
Ad scientiam
See details and how to joinNCT07323316
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Altenburg, Berlin, Goettingen, Wuerzburg
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Berlin, Essen
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 3Taking people
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Where
Altenburg, Bochum, Erlangen, Freiburg im Breisgau, Muenster, Rüdersdorf
Age
18 years to 74 years
People
115 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00
Phase 3Taking people
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Where
Freiburg im Breisgau
Age
18 years to 80 years
People
195 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Berlin, Göttingen, Würzburg
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Berlin, Bochum, Dresden, Duesseldorf, Goettingen, Gummersbach, Hanover, Leipzig, Luebeck, Ulm
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Essen
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Altenburg, Berlin, Goettingen, Wuerzburg
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 1/2Not yet taking people in Germany
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
Where
Hamburg, Muenster, Munich
Age
18 years and over
People
55 worldwide
Run by
Bonsai Biotherapeutics AB
See details and how to join2024-515627-10-00 · EU 2024-515627-10-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Where
Bochum, Essen, Goettingen, Magdeburg, Wuerzburg
Age
18 years to 80 years
People
231 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00
Phase 2/3Taking people
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Where
Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich
Age
18 years to 75 years
People
66 worldwide
Run by
Kyverna Therapeutics
See details and how to joinNCT06193889 · EU 2023-509892-17-00
No phaseTaking people
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Where
Essen
People
75 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06312644
Phase 4Taking people
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Where
Bochum
Age
18 years and over
People
75 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07221838 · EU 2025-522555-26-00
No phaseTaking people
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Where
Hanover
Age
18 years and over
People
500 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341
No phaseTaking people
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Where
Altenburg, Bochum, Göppingen, Göttingen, Gummersbach, Jena, Würzburg
Age
18 years and over
People
680 worldwide
Run by
argenx
See details and how to joinNCT06298565
No phaseTaking people
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Where
Bochum
People
279 worldwide
Run by
argenx
See details and how to joinNCT06299748
Phase 2/3Taking people
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Where
Berlin, Bochum, Hamburg, Hanover
Age
18 years and over
People
70 worldwide
Run by
Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00
No phaseEnrolling by invitation
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Where
München
Age
18 years to 65 years
People
108
Run by
LMU Klinikum
See details and how to joinNCT06605612